RARE DISEASERESEARCH ATLAS

ORPHA:35173

X-linked dominant chondrodysplasia punctata

medium confidenceDisorder

Also known as: CDPX2 · CDPXD · CPXD · Chondrodystrophia calcificans congenita · Conradi-Hünermann-Happle syndrome · X-linked chondrodysplasia punctata type 2

Query health: suspect — Only one of 2 strategies returned hits (phrase).

Publications

1,654

92.9th percentile

Trials

0

Interventional, condition-specific

Researchers

1,115

Distinct authors in sample

Gene link

EBP

Definitive

Readiness

2/6

Stages with a signal

Clinical definition (Orphanet)

A rare genodermatosis disease with great phenotypic variation and characterized most commonly by ichthyosis following the lines of Blaschko, chondrodysplasia punctata (CDP), asymmetric shortening of the limbs, cataracts and short stature.

How rare: 1-9 / 1 000 000 — roughly one to nine people per million. In a city the size of Kolkata, perhaps a few dozen.

Orphanet entry

Cross-references

Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.

Additional Mondo synonyms (11)

Conrad Hunermann Happle syndrome · Conradi Hunermann syndrome · Conradi Hünermann Syndrome · Conradi-Hunermann syndrome · Conradi-Hunermann-Happle syndrome · EBP chondrodysplasia punctata · Happle syndrome · chondrodysplasia punctata 2 X-linked dominant · chondrodysplasia punctata 2, X-linked dominant · chondrodysplasia punctata caused by mutation in EBP · chondrodysplasia punctata, X-linked dominant, X-linked dominant

Research stages

Trial readiness signals

Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”

2/6 stages with a signal

No matched interventional trial; the gene is known and literature exists — preclinical or natural-history work may still be the practical next step.

  1. Gene identifiedPresent

    Definitive — EBP

  2. LiteraturePresent

    1,654 matched papers (914 in last 10 years) Source

  3. Phenotype characterisedNot checked

    Not yet enriched from Monarch / HPO

  4. Animal modelNot checked

    Not yet enriched from Monarch / Alliance

  5. Orphan designationNot checked

    FDA/EMA orphan-drug designation not enriched yet

  6. Interventional trialNot found

    No matched interventional trial under our ClinicalTrials.gov rules

Biology

Genes and phenotypes

Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.

Do we know what causes it?

Yes — we know a specific gene responsible (EBP).

GenCC classification: Definitive.

Phenotypes (Monarch / HPO)

Not enriched in this build — Monarch phenotype joins were not run for this record.

Animal models (Monarch / Alliance)

Not enriched in this build.

Literature

Is anyone studying this?

1,654

1,654 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.

1,654 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).

914 in the last 10 years · medium confidence · 92.9th percentile (publications denominator)

Phrase hits: 1,654 · MeSH hits: 0

Open Europe PMC search

Who's working on it?

1,115

Distinct author names in 200 sampled papers — named people below.

Who's working on it?

No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.

  1. 01
    Hoyt JR11 papers · 2026

    Department of Biological Sciences, Virginia Polytechnic Institute, Blacksburg, Virginia, USA.

    Papers in Europe PMC
  2. 02
    Langwig KE10 papers · 2026

    Department of Biological Sciences, Virginia Polytechnic Institute, Blacksburg, Virginia, USA.

    Papers in Europe PMC
  3. 03
    White JP8 papers · 2026

    Wisconsin Department of Natural Resources, Madison, Wisconsin, USA.

    Papers in Europe PMC
  4. 04
    DePue JE7 papers · 2026

    Michigan Department of Natural Resources, Baraga, Michigan, USA.

    Papers in Europe PMC
  5. 05
    Kaarakka HM7 papers · 2026

    Wisconsin Department of Natural Resources, Madison, Wisconsin, USA.

    Papers in Europe PMC
  6. 06
    Redell JA7 papers · 2026

    Wisconsin Department of Natural Resources, Madison, Wisconsin, USA.

    Papers in Europe PMC
  7. 07
    Foster JT6 papers · 2025

    Pathogen and Microbiome Institute, Northern Arizona University, Flagstaff, Arizona, USA.

    Papers in Europe PMC
  8. 08
    Fischer J5 papers · 2026

    Institute of Human Genetics, Medical Faculty and Medical Center, University of Freiburg, Freiburg, Germany.

    Papers in Europe PMC
  9. 09
    Kilpatrick AM5 papers · 2023

    Department of Ecology and Evolutionary Biology, University of California, Santa Cruz, Santa Cruz, California, USA.

    Papers in Europe PMC
  10. 10
    Parise KL5 papers · 2023

    Pathogen and Microbiome Institute, Northern Arizona University, Flagstaff, Arizona, USA.

    Papers in Europe PMC

Clinical research

Is a treatment being tested?

0

interventional trials for this specific condition

No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present).

Data as of 27 July 2026

No matched interventional trials. This is true for 73% of diseases in the trials denominator (5114 of 7003). Here are the researchers publishing on it.

medium confidence · 36.5th percentile (trials denominator)

Recruiting interventional trials

From the matched ClinicalTrials.gov set

No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.

See who's working on it — people publishing on this disease are often the practical next contact when no trial is listed.

Where to find support

We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:

India — NPRD

Last verified 2026-07-26

This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.

Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.

How we counted this

Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.

"X-linked dominant chondrodysplasia punctata" OR "CDPX2" OR "CDPXD" OR "Chondrodystrophia calcificans congenita" OR "Conradi-Hünermann-Happle syndrome" OR "X-linked chondrodysplasia punctata type 2" OR "Conrad Hunermann Happle syndrome" OR "Conradi Hunermann syndrome" OR "Conradi Hünermann Syndrome" OR "Conradi-Hunermann syndrome" OR "Conradi-Hunermann-Happle syndrome" OR "EBP chondrodysplasia punctata" OR "Happle syndrome" OR "chondrodysplasia punctata 2 X-linked dominant" OR "chondrodysplasia punctata 2, X-linked dominant" OR "chondrodysplasia punctata caused by mutation in EBP" OR "chondrodysplasia punctata, X-linked dominant, X-linked dominant"

Run this search on Europe PMC

ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):

"X-linked dominant chondrodysplasia punctata" OR "CDPX2" OR "CDPXD" OR "Chondrodystrophia calcificans congenita" OR "Conradi-Hünermann-Happle syndrome" OR "X-linked chondrodysplasia punctata type 2" OR "Conrad Hunermann Happle syndrome" OR "Conradi Hunermann syndrome" OR "Conradi Hünermann Syndrome" OR "Conradi-Hunermann syndrome" OR "Conradi-Hunermann-Happle syndrome" OR "EBP chondrodysplasia punctata" OR "Happle syndrome" OR "chondrodysplasia punctata 2 X-linked dominant" OR "chondrodysplasia punctata 2, X-linked dominant" OR "chondrodysplasia punctata caused by mutation in EBP" OR "chondrodysplasia punctata, X-linked dominant, X-linked dominant" OR "EBP" OR "X-linked chondrodysplasia punctata" OR "non-rhizomelic chondrodysplasia punctata"

Recall-expansion terms: EBP, X-linked chondrodysplasia punctata, non-rhizomelic chondrodysplasia punctata

Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.

Query health: suspect — strategies attempted: phrase, recall-expansion; with hits: phrase

Run this search on ClinicalTrials.gov

Synonyms dropped by stoplist: CPXD

Confidence reasoning

  • Preferred label is multi-word and distinctive
  • 1 synonym(s) dropped by stoplist (may under-count)
  • No label/synonym collisions with other diseases in this corpus

Ingested 2026-07-26T23:45:54.616Z